FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2055332637> ?p ?o ?g. }

• W2055332637 endingPage "2169" @default.
• W2055332637 startingPage "2161" @default.
• W2055332637 abstract "Background Based on our previous results showing the involvement of the farnesylated form of RhoB in glioblastoma radioresistance, we designed a phase II trial associating the farnesyltransferase inhibitor Tipifarnib with radiotherapy in patients with glioblastoma and studied the prognostic values of the proteins which we have previously shown control this pathway. Patients and methods Patients were treated with 200 mg Tipifarnib (recommended dose (RD)) given continuously during radiotherapy. Twenty-seven patients were included in the phase II whose primary end-point was time to progression (TTP). Overall survival (OS) and biomarker analysis were secondary end-points. Expressions of αvβ3, αvβ5 integrins, FAK, ILK, fibroblast growth factor 2 (FGF2) and fibroblast growth factor receptor 1 (FGFR1) were studied by immuno-histochemistry in the tumour of the nine patients treated at the RD during the previously performed phase I and on those of the phase II patients. We evaluated the correlation of the expressions of these proteins with the clinical outcome. Results For the phase II patients median TTP was 23.1 weeks (95%CI = [15.4; 28.2]) while the median OS was 80.3 weeks (95%CI = [57.8; 102.7]). In the pooled phase I and II population, median OS was 60.4w (95%CI = [47.3; 97.6]) while median TTP was 18.1w (95%CI = [16.9; 25.6]). FGFR1 over-expression (HR = 4.65; 95%CI = [1.02; 21.21], p = 0.047) was correlated with shorter TTP while FGFR1 (HR = 4.1 (95% CI = [1.09–15.4]; p = 0.036)) and αvβ3 (HR = 10.38 (95%CI = [2.70; 39.87], p = 0.001)) over-expressions were associated with reduced OS. Conclusion Association of 200 mg Tipifarnib with radiotherapy shows promising OS but no increase in TTP compared to historical data. FGFR1 and αvβ3 integrin are independent bad prognostic factors of OS and TTP." @default.
• W2055332637 created "2016-06-24" @default.
• W2055332637 creator A5003424696 @default.
• W2055332637 creator A5006552617 @default.
• W2055332637 creator A5006574905 @default.
• W2055332637 creator A5025466073 @default.
• W2055332637 creator A5029499960 @default.
• W2055332637 creator A5036138088 @default.
• W2055332637 creator A5041166804 @default.
• W2055332637 creator A5046580775 @default.
• W2055332637 creator A5049146353 @default.
• W2055332637 creator A5053269660 @default.
• W2055332637 creator A5056915781 @default.
• W2055332637 creator A5060829795 @default.
• W2055332637 creator A5061992932 @default.
• W2055332637 creator A5072386149 @default.
• W2055332637 creator A5075378844 @default.
• W2055332637 date "2013-06-01" @default.
• W2055332637 modified "2023-10-16" @default.
• W2055332637 title "αvβ3 Integrin and Fibroblast growth factor receptor 1 (FGFR1): Prognostic factors in a phase I–II clinical trial associating continuous administration of Tipifarnib with radiotherapy for patients with newly diagnosed glioblastoma" @default.
• W2055332637 cites W1501059115 @default.
• W2055332637 cites W1972024414 @default.
• W2055332637 cites W1984345624 @default.
• W2055332637 cites W1995567710 @default.
• W2055332637 cites W2006491169 @default.
• W2055332637 cites W2010991958 @default.
• W2055332637 cites W2014199603 @default.
• W2055332637 cites W2032131447 @default.
• W2055332637 cites W2044136921 @default.
• W2055332637 cites W2071667499 @default.
• W2055332637 cites W2073712871 @default.
• W2055332637 cites W2074342349 @default.
• W2055332637 cites W2079252535 @default.
• W2055332637 cites W2080208032 @default.
• W2055332637 cites W2083771852 @default.
• W2055332637 cites W2093616734 @default.
• W2055332637 cites W2096287682 @default.
• W2055332637 cites W2105100844 @default.
• W2055332637 cites W2118691735 @default.
• W2055332637 cites W2127449225 @default.
• W2055332637 cites W2132607958 @default.
• W2055332637 cites W2139676810 @default.
• W2055332637 cites W2152453061 @default.
• W2055332637 cites W2160382843 @default.
• W2055332637 cites W2166636543 @default.
• W2055332637 cites W2313149858 @default.
• W2055332637 cites W2331825483 @default.
• W2055332637 doi "https://doi.org/10.1016/j.ejca.2013.02.033" @default.
• W2055332637 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23566417" @default.
• W2055332637 hasPublicationYear "2013" @default.
• W2055332637 type Work @default.
• W2055332637 sameAs 2055332637 @default.
• W2055332637 citedByCount "43" @default.
• W2055332637 countsByYear W20553326372014 @default.
• W2055332637 countsByYear W20553326372015 @default.
• W2055332637 countsByYear W20553326372016 @default.
• W2055332637 countsByYear W20553326372017 @default.
• W2055332637 countsByYear W20553326372018 @default.
• W2055332637 countsByYear W20553326372019 @default.
• W2055332637 countsByYear W20553326372020 @default.
• W2055332637 countsByYear W20553326372021 @default.
• W2055332637 countsByYear W20553326372022 @default.
• W2055332637 countsByYear W20553326372023 @default.
• W2055332637 crossrefType "journal-article" @default.
• W2055332637 hasAuthorship W2055332637A5003424696 @default.
• W2055332637 hasAuthorship W2055332637A5006552617 @default.
• W2055332637 hasAuthorship W2055332637A5006574905 @default.
• W2055332637 hasAuthorship W2055332637A5025466073 @default.
• W2055332637 hasAuthorship W2055332637A5029499960 @default.
• W2055332637 hasAuthorship W2055332637A5036138088 @default.
• W2055332637 hasAuthorship W2055332637A5041166804 @default.
• W2055332637 hasAuthorship W2055332637A5046580775 @default.
• W2055332637 hasAuthorship W2055332637A5049146353 @default.
• W2055332637 hasAuthorship W2055332637A5053269660 @default.
• W2055332637 hasAuthorship W2055332637A5056915781 @default.
• W2055332637 hasAuthorship W2055332637A5060829795 @default.
• W2055332637 hasAuthorship W2055332637A5061992932 @default.
• W2055332637 hasAuthorship W2055332637A5072386149 @default.
• W2055332637 hasAuthorship W2055332637A5075378844 @default.
• W2055332637 hasConcept C126322002 @default.
• W2055332637 hasConcept C126894567 @default.
• W2055332637 hasConcept C143998085 @default.
• W2055332637 hasConcept C170493617 @default.
• W2055332637 hasConcept C203092338 @default.
• W2055332637 hasConcept C2776694085 @default.
• W2055332637 hasConcept C2908647359 @default.
• W2055332637 hasConcept C31760486 @default.
• W2055332637 hasConcept C49418065 @default.
• W2055332637 hasConcept C509974204 @default.
• W2055332637 hasConcept C535046627 @default.
• W2055332637 hasConcept C71924100 @default.
• W2055332637 hasConcept C74373430 @default.
• W2055332637 hasConcept C90924648 @default.
• W2055332637 hasConcept C99454951 @default.
• W2055332637 hasConceptScore W2055332637C126322002 @default.
• W2055332637 hasConceptScore W2055332637C126894567 @default.
• W2055332637 hasConceptScore W2055332637C143998085 @default.
• W2055332637 hasConceptScore W2055332637C170493617 @default.

• next